Aduro BioTech Stock Price, News & Analysis (NASDAQ:ADRO)

$6.10 +0.05 (+0.83 %)
(As of 02/21/2018 01:59 AM ET)
Previous Close$6.10
Today's Range$6.05 - $6.20
52-Week Range$5.82 - $14.05
Volume344,265 shs
Average Volume511,353 shs
Market Capitalization$471.55 million
P/E Ratio-4.49
Dividend YieldN/A
BetaN/A

About Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech logoAduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ADRO
CUSIPN/A
Phone+1-510-8484400

Debt

Debt-to-Equity RatioN/A
Current Ratio10.62%
Quick Ratio10.62%

Price-To-Earnings

Trailing P/E Ratio-4.48529411764706
Forward P/E Ratio-4.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$50.68 million
Price / Sales9.30
Cash FlowN/A
Price / CashN/A
Book Value$3.38 per share
Price / Book1.80

Profitability

Trailing EPS($1.36)
Net Income$-91,140,000.00
Net Margins-548.92%
Return on Equity-39.28%
Return on Assets-21.15%

Miscellaneous

Employees158
Outstanding Shares77,300,000

Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) released its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.03. The biotechnology company earned $3.79 million during the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm's revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.54) EPS. View Aduro BioTech's Earnings History.

Where is Aduro BioTech's stock going? Where will Aduro BioTech's stock price be in 2018?

8 brokers have issued 1 year target prices for Aduro BioTech's stock. Their forecasts range from $10.00 to $30.00. On average, they anticipate Aduro BioTech's stock price to reach $18.50 in the next twelve months. View Analyst Ratings for Aduro BioTech.

What are Wall Street analysts saying about Aduro BioTech stock?

Here are some recent quotes from research analysts about Aduro BioTech stock:

  • 1. HC Wainwright analysts commented, "All Three Platforms Now Clinical Stage; We Have High Expectations for B-Select Platform B-select investment starts bearing clinical stage candidates. Aduro announced the expected initiation of a Phase 1/2 clinical trial with its anti-APRIL antibody, BION-1301. This two part, open-label study, is being conducted in relapsed or refractory multiple myeloma patients (at least three prior systemic therapies). Once the recommended Phase 2 dose is identified in part 1, patients are to be expanded at the selected dose with the primary endpoint of overall response rate. The APRIL/BCMA pathway was also a hot topic at the recent ASH conference as an encouraging new target against myeloma. A proliferation inducing ligand (APRIL) is one of the main high affinity ligands that binds and activates BCMA resulting in a pro-survival cell signal. APRIL is a member of the TNF family and is overexpressed in patients with multiple myeloma (MM)." (12/13/2017)
  • 2. According to Zacks Investment Research, "Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (8/2/2017)
  • 3. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
  • 4. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)

Who are some of Aduro BioTech's key competitors?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the folowing people:

  • Stephen T. Isaacs, Chairman of the Board, President and Chief Executive Officer (Age 68)
  • Jennifer Lew CPA, Chief Financial Officer (Age 45)
  • Gregory W. Schafer, Chief Operating Officer (Age 52)
  • Blaine Templeman, Executive Vice President, General Counsel, Secretary (Age 51)
  • Dirk G. Brockstedt, Executive Vice President of Research and Development (Age 48)
  • Andrea van Elsas Ph.D., Chief Scientific Officer
  • Natalie R. Sacks, Chief Medical Officer (Age 52)
  • Stephanie Monaghan O'Brien J.D., Lead Independent Director (Age 58)
  • Gerald Chan Ph.D., Independent Director (Age 66)
  • William M. Greenman, Independent Director (Age 50)

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who owns Aduro BioTech stock?

Aduro BioTech's stock is owned by many different of institutional and retail investors. Top institutional investors include Harvard Management Co. Inc. (5.40%), BlackRock Inc. (4.66%), NOVARTIS AG (4.10%), Deutsche Bank AG (0.85%), Geode Capital Management LLC (0.46%) and Renaissance Technologies LLC (0.41%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro BioTech.

Who sold Aduro BioTech stock? Who is selling Aduro BioTech stock?

Aduro BioTech's stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Renaissance Technologies LLC, BlackRock Inc., Deutsche Bank AG, Schwab Charles Investment Management Inc., Foundry Partners LLC and Wells Fargo & Company MN. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Stephen T Isaacs and Thomas W Dubensky. View Insider Buying and Selling for Aduro BioTech.

Who bought Aduro BioTech stock? Who is buying Aduro BioTech stock?

Aduro BioTech's stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Goldman Sachs Group Inc., Two Sigma Investments LP, Spark Investment Management LLC, Alliancebernstein L.P., Vident Investment Advisory LLC, Virtus Fund Advisers LLC and Geode Capital Management LLC. View Insider Buying and Selling for Aduro BioTech.

How do I buy Aduro BioTech stock?

Shares of Aduro BioTech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of Aduro BioTech stock can currently be purchased for approximately $6.10.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $471.55 million and generates $50.68 million in revenue each year. The biotechnology company earns $-91,140,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Aduro BioTech employs 158 workers across the globe.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 Heinz Ave, BERKELEY, CA 94710-2748, United States. The biotechnology company can be reached via phone at +1-510-8484400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (ADRO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  392
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aduro BioTech (NASDAQ:ADRO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.50$18.50$20.17$20.00
Price Target Upside: 158.74% upside158.74% upside153.67% upside68.07% upside

Aduro BioTech (NASDAQ:ADRO) Consensus Price Target History

Price Target History for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ:ADRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
12/14/2017Canaccord GenuitySet Price TargetBuy$30.00MediumView Rating Details
12/13/2017OppenheimerLower Price TargetOutperform$15.00 -> $13.00HighView Rating Details
10/2/2017William BlairReiterated RatingOutperformHighView Rating Details
7/18/2017CowenInitiated CoverageOutperformLowView Rating Details
5/1/2017Rodman & RenshawInitiated CoverageBuy -> Buy$18.00LowView Rating Details
3/7/2017FBR & CoReiterated RatingBuy$23.00N/AView Rating Details
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/AView Rating Details
10/24/2016Leerink SwannSet Price TargetBuy$14.00N/AView Rating Details
3/15/2016Bank of AmericaDowngradeBuy -> Underperform$32.00 -> $14.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Aduro BioTech (NASDAQ:ADRO) Earnings History and Estimates Chart

Earnings by Quarter for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ ADRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.30)($0.33)$4.04 million$3.79 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.25)($0.27)$3.98 million$5.90 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.39)($0.32)$3.74 million$3.77 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.40)($0.44)$3.83 million$3.88 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.45)($0.54)$3.99 million$3.79 millionViewN/AView Earnings Details
8/3/2016Q2 2016($0.18)$0.03$25.24 million$39.00 millionViewN/AView Earnings Details
5/2/2016Q116($0.25)($0.45)$13.47 million$4.03 millionViewN/AView Earnings Details
3/8/2016Q415($0.15)$0.04$17.55 million$34.38 millionViewN/AView Earnings Details
11/23/2015Q3($0.08)$0.01$15.80 million$19.15 millionViewN/AView Earnings Details
8/10/2015Q215($0.01)($0.18)$1.00 million$9.90 millionViewN/AView Earnings Details
5/28/2015Q115($0.08)($39.97)$12.03 million$9.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aduro BioTech (NASDAQ:ADRO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.41)($0.24)($0.31)
Q2 20183($0.42)($0.19)($0.29)
Q3 20183($0.43)($0.20)($0.31)
Q4 20183($0.42)($0.21)($0.31)
Q1 20191($0.44)($0.44)($0.44)
Q2 20191($0.47)($0.47)($0.47)
Q3 20191($0.47)($0.47)($0.47)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Aduro BioTech (NASDAQ:ADRO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aduro BioTech (NASDAQ ADRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 42.61%
Insider Trades by Quarter for Aduro BioTech (NASDAQ:ADRO)
Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech (NASDAQ ADRO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Stephen T IsaacsInsiderSell7,949$7.95$63,194.55213,695View SEC Filing  
1/2/2018Gregory W SchaferCOOSell20,000$7.61$152,200.00190,745View SEC Filing  
12/18/2017Blaine TemplemanVPSell2,884$8.25$23,793.0069,937View SEC Filing  
12/15/2017Dirk G BrockstedtEVPSell65,223$8.11$528,958.53137,826View SEC Filing  
12/1/2017Dirk G BrockstedtEVPSell10,000$9.40$94,000.0077,674View SEC Filing  
12/1/2017Gregory W SchaferCOOSell20,000$9.34$186,800.00155,676View SEC Filing  
12/1/2017Jennifer LewVPSell6,600$9.46$62,436.0068,938View SEC Filing  
12/1/2017Stephen T IsaacsInsiderSell40,000$9.38$375,200.00213,921View SEC Filing  
11/17/2017Blaine TemplemanVPSell243$8.85$2,150.55View SEC Filing  
11/15/2017Jennifer LewInsiderSell6,600$8.95$59,070.0068,938View SEC Filing  
11/13/2017Dirk G BrockstedtEVPSell5,877$8.00$47,016.0075,533View SEC Filing  
11/13/2017Stephen T IsaacsInsiderSell19,800$7.97$157,806.00190,321View SEC Filing  
11/10/2017Dirk G BrockstedtEVPSell1,815$8.01$14,538.1575,533View SEC Filing  
11/10/2017Stephen T IsaacsCEOSell16,400$7.96$130,544.00190,321View SEC Filing  
11/7/2017Stephen T IsaacsInsiderSell20,200$7.98$161,196.00190,321View SEC Filing  
11/6/2017Dirk G BrockstedtEVPSell4,123$8.04$33,148.9277,841View SEC Filing  
11/6/2017Gregory W SchaferCOOSell20,000$7.97$159,400.00155,677View SEC Filing  
10/2/2017Dirk G BrockstedtEVPSell10,000$10.59$105,900.00View SEC Filing  
10/2/2017Gregory W SchaferCOOSell20,000$10.75$215,000.00View SEC Filing  
10/2/2017Jennifer LewInsiderSell6,600$10.61$70,026.00View SEC Filing  
10/2/2017Stephen T IsaacsCEOSell40,000$10.78$431,200.00213,921View SEC Filing  
9/18/2017Blaine TemplemanVPSell2,884$11.20$32,300.8058,834View SEC Filing  
9/13/2017Blaine TemplemanVPSell3,557$10.99$39,091.4365,275View SEC Filing  
9/13/2017Elsas Andrea VanInsiderSell4,922$10.99$54,092.78212,153View SEC Filing  
9/13/2017Gregory W SchaferCOOSell4,859$10.99$53,400.41153,604View SEC Filing  
9/1/2017Dirk G BrockstedtEVPSell10,000$11.69$116,900.0059,300View SEC Filing  
9/1/2017Gregory W SchaferCOOSell20,000$11.70$234,000.00131,645View SEC Filing  
9/1/2017Jennifer LewInsiderSell6,600$11.70$77,220.0049,195View SEC Filing  
8/11/2017Thomas W DubenskyInsiderSell50,000$11.38$569,000.0080,812View SEC Filing  
8/10/2017Thomas W DubenskyInsiderSell40,912$11.43$467,624.1680,812View SEC Filing  
8/8/2017Gregory W SchaferCOOSell40,000$12.17$486,800.00133,879View SEC Filing  
8/7/2017Dirk G BrockstedtEVPSell10,000$12.18$121,800.0059,300View SEC Filing  
8/7/2017Gregory W SchaferCOOSell25,811$12.17$314,119.87133,879View SEC Filing  
8/7/2017Jennifer LewInsiderSell6,600$12.17$80,322.0049,195View SEC Filing  
8/7/2017Stephen T IsaacsCEOSell40,000$12.19$487,600.00144,025View SEC Filing  
7/6/2017Thomas W DubenskyInsiderSell50,000$11.33$566,500.0051,700View SEC Filing  
7/5/2017Stephen T IsaacsInsiderSell40,000$11.06$442,400.00132,093View SEC Filing  
7/3/2017Dirk G BrockstedtEVPSell10,000$11.02$110,200.0053,956View SEC Filing  
7/3/2017Jennifer LewInsiderSell12,000$11.14$133,680.0054,595View SEC Filing  
6/28/2017Gregory W SchaferCOOSell40,000$11.26$450,400.00160,979View SEC Filing  
6/28/2017Jennifer LewInsiderSell12,000$11.19$134,280.0054,595View SEC Filing  
6/19/2017Stephen T IsaacsInsiderSell40,000$10.50$420,000.00125,486View SEC Filing  
6/5/2017Thomas W DubenskyInsiderSell144,301$10.03$1,447,339.03117,871View SEC Filing  
5/17/2017Blaine TemplemanVPSell1,648$9.65$15,903.20View SEC Filing  
5/17/2017Dirk G. BrockstedtEVPSell1,011$9.65$9,756.15View SEC Filing  
5/16/2017Stephen T. IsaacsCEOSell16,673$10.00$166,730.00View SEC Filing  
5/16/2017Stephen T. IsaacsinsiderSell27,273$10.01$273,002.73View SEC Filing  
5/15/2017Stephen T. IsaacsCEOSell10,600$10.01$106,106.00View SEC Filing  
5/12/2017Thomas W DubenskyInsiderSell5,699$9.92$56,534.0841,300View SEC Filing  
5/11/2017Dirk G BrockstedtEVPSell8,000$9.72$77,760.0057,300View SEC Filing  
4/3/2017Dirk G BrockstedtEVPSell8,000$10.71$85,680.0057,300View SEC Filing  
4/3/2017Stephen T IsaacsInsiderSell27,273$10.28$280,366.44129,473View SEC Filing  
3/13/2017Stephen T IsaacsInsiderSell27,273$11.35$309,548.55129,473View SEC Filing  
3/9/2017Dirk G BrockstedtEVPSell8,000$11.00$88,000.0057,300View SEC Filing  
3/9/2017Thomas W DubenskyInsiderSell25,000$10.96$274,000.0054,804View SEC Filing  
1/17/2017Dirk G BrockstedtEVPSell8,000$11.86$94,880.0057,300View SEC Filing  
1/11/2017Blaine TemplemanVPSell3,785$11.95$45,230.75View SEC Filing  
1/3/2017Stephen T IsaacsInsiderSell27,273$11.12$303,275.76119,896View SEC Filing  
12/1/2016Thomas W DubenskyInsiderSell25,000$10.94$273,500.0053,763View SEC Filing  
11/14/2016Ross HaghighatDirectorSell7,088$15.50$109,864.00View SEC Filing  
10/3/2016Stephen T IsaacsCEOSell27,273$12.67$345,548.91129,473View SEC Filing  
10/3/2016Thomas W DubenskyInsiderSell25,000$12.68$317,000.0055,424View SEC Filing  
9/19/2016Jennifer LewInsiderSell6,360$14.95$95,082.0048,955View SEC Filing  
9/1/2016Thomas W DubenskyInsiderSell25,000$14.03$350,750.0016,407View SEC Filing  
8/11/2016Thomas W DubenskyInsiderSell25,000$15.18$379,500.0012,500View SEC Filing  
7/5/2016Thomas W DubenskyInsiderSell25,000$11.61$290,250.0013,939View SEC Filing  
5/16/2016Thomas W. DubenskyInsiderSell905$8.20$7,421.00View SEC Filing  
1/11/2016Dirk G. BrockstedtVPSell22,000$21.77$478,940.0012,000View SEC Filing  
1/8/2016Gregory W. SchaferCOOSell20,000$23.58$471,600.0049,279View SEC Filing  
1/6/2016Jennifer LewVPSell5,242$25.71$134,771.826,200View SEC Filing  
1/5/2016Stephen T. IsaacsCEOSell25,000$26.31$657,750.0010,000View SEC Filing  
1/4/2016Thomas W. DubenskyinsiderSell15,000$26.37$395,550.00View SEC Filing  
12/7/2015Gregory W. SchaferCOOSell25,000$29.74$743,500.0034,279View SEC Filing  
12/3/2015Jennifer LewVPSell5,242$29.85$156,473.702,000View SEC Filing  
12/1/2015Stephen T. IsaacsCEOSell25,000$29.11$727,750.00View SEC Filing  
12/1/2015Thomas W. DubenskyinsiderSell30,000$29.27$878,100.00View SEC Filing  
11/18/2015Jennifer LewVPSell6,712$28.52$191,426.242,000View SEC Filing  
11/17/2015Gregory W. SchaferCOOSell26,470$28.15$745,130.5034,279View SEC Filing  
11/17/2015Thomas W. DubenskyinsiderSell31,470$28.27$889,656.90View SEC Filing  
11/16/2015Stephen T. IsaacsCEOSell25,000$27.54$688,500.00View SEC Filing  
4/20/2015Jennifer LewVPBuy2,000$17.00$34,000.00View SEC Filing  
4/20/2015Venture (Vi) Inves MorningsideMajor ShareholderBuy441,176$17.00$7,499,992.00View SEC Filing  
4/20/2015William Mariner GreenmanDirectorBuy3,000$17.00$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aduro BioTech (NASDAQ ADRO) News Headlines

Source:
DateHeadline
Aduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceAduro Biotech to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:44 AM
$4.32 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter$4.32 Million in Sales Expected for Aduro BioTech Inc (ADRO) This Quarter
www.americanbankingnews.com - February 7 at 8:54 AM
-$0.36 EPS Expected for Aduro BioTech Inc (ADRO) This Quarter-$0.36 EPS Expected for Aduro BioTech Inc (ADRO) This Quarter
www.americanbankingnews.com - February 5 at 1:10 AM
Aduro BioTech (ADRO) Cut to "Strong Sell" at BidaskClubAduro BioTech (ADRO) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 2:44 PM
Aduro BioTech Inc (ADRO) Given Average Recommendation of "Buy" by BrokeragesAduro BioTech Inc (ADRO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 2 at 1:03 PM
Aduro BioTech Inc (ADRO) Expected to Post Quarterly Sales of $4.32 MillionAduro BioTech Inc (ADRO) Expected to Post Quarterly Sales of $4.32 Million
www.americanbankingnews.com - January 21 at 12:40 PM
Zacks: Brokerages Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 EPSZacks: Brokerages Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 EPS
www.americanbankingnews.com - January 19 at 3:30 AM
Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 7,949 Shares of StockInsider Selling: Aduro BioTech Inc (ADRO) Insider Sells 7,949 Shares of Stock
www.americanbankingnews.com - January 9 at 7:16 PM
Aduro BioTech Inc (ADRO) Receives Average Recommendation of "Buy" from AnalystsAduro BioTech Inc (ADRO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 8 at 6:02 AM
Aduro Biotech (ADRO) Names Jennifer Lew as CFO; Gregory W. Schafer to Step Down as COO - StreetInsider.comAduro Biotech (ADRO) Names Jennifer Lew as CFO; Gregory W. Schafer to Step Down as COO - StreetInsider.com
www.streetinsider.com - January 7 at 3:49 PM
Aduro Biotech (ADRO) Names Jennifer Lew as CFO; Gregory W. Schafer to Step Down as COOAduro Biotech (ADRO) Names Jennifer Lew as CFO; Gregory W. Schafer to Step Down as COO
www.streetinsider.com - January 6 at 9:37 AM
Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 10:52 AM
Aduro Biotech Announces Management ChangesAduro Biotech Announces Management Changes
finance.yahoo.com - January 5 at 10:52 AM
Gregory W. Schafer Sells 20,000 Shares of Aduro BioTech Inc (ADRO) StockGregory W. Schafer Sells 20,000 Shares of Aduro BioTech Inc (ADRO) Stock
www.americanbankingnews.com - January 3 at 9:52 PM
Zacks: Brokerages Expect Aduro BioTech Inc (ADRO) to Post -$0.36 EPSZacks: Brokerages Expect Aduro BioTech Inc (ADRO) to Post -$0.36 EPS
www.americanbankingnews.com - January 2 at 9:30 AM
Critical Comparison: Catabasis Pharmaceuticals (CATB) and Aduro BioTech (ADRO)Critical Comparison: Catabasis Pharmaceuticals (CATB) and Aduro BioTech (ADRO)
www.americanbankingnews.com - January 1 at 5:30 AM
ETFs with exposure to Aduro BioTech, Inc. : December 29, 2017ETFs with exposure to Aduro BioTech, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 3:33 PM
This Mornings Technical Outlook on Biotech Stocks -- Alnylam Pharma, Celldex Therapeutics, Aduro BioTech, and Zosano PharmaThis Morning's Technical Outlook on Biotech Stocks -- Alnylam Pharma, Celldex Therapeutics, Aduro BioTech, and Zosano Pharma
www.bizjournals.com - December 27 at 1:26 PM
HC Wainwright Analysts Give Aduro BioTech (ADRO) a $10.00 Price TargetHC Wainwright Analysts Give Aduro BioTech (ADRO) a $10.00 Price Target
www.americanbankingnews.com - December 24 at 5:46 PM
Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent - GlobeNewswire (press release)Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent - GlobeNewswire (press release)
globenewswire.com - December 22 at 4:12 PM
Blaine Templeman Sells 2,884 Shares of Aduro BioTech Inc (ADRO) StockBlaine Templeman Sells 2,884 Shares of Aduro BioTech Inc (ADRO) Stock
www.americanbankingnews.com - December 20 at 8:58 PM
Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued PatentAduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent
finance.yahoo.com - December 20 at 10:59 AM
Aduro Biotech (ADRO) Reports First Patients in Phase 1/2 Clinical Trial of BION-1301 - StreetInsider.comAduro Biotech (ADRO) Reports First Patients in Phase 1/2 Clinical Trial of BION-1301 - StreetInsider.com
www.streetinsider.com - December 19 at 3:33 PM
Aduro Biotech (ADRO) Reports First Patients in Phase 1/2 Clinical Trial of BION-1301Aduro Biotech (ADRO) Reports First Patients in Phase 1/2 Clinical Trial of BION-1301
www.streetinsider.com - December 19 at 11:20 AM
ETFs with exposure to Aduro BioTech, Inc. : December 18, 2017ETFs with exposure to Aduro BioTech, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:32 PM
Zacks: Brokerages Anticipate Aduro BioTech Inc (ADRO) Will Post Quarterly Sales of $4.32 MillionZacks: Brokerages Anticipate Aduro BioTech Inc (ADRO) Will Post Quarterly Sales of $4.32 Million
www.americanbankingnews.com - December 18 at 3:08 PM
Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple MyelomaAduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma
finance.yahoo.com - December 18 at 11:08 AM
Aduro BioTech (ADRO) Price Target Cut to $9.50Aduro BioTech (ADRO) Price Target Cut to $9.50
www.americanbankingnews.com - December 17 at 9:24 AM
 Analysts Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 Earnings Per Share Analysts Anticipate Aduro BioTech Inc (ADRO) to Post -$0.36 Earnings Per Share
www.americanbankingnews.com - December 16 at 3:26 PM
Oppenheimer Weighs in on Aduro BioTech Incs FY2020 Earnings (ADRO)Oppenheimer Weighs in on Aduro BioTech Inc's FY2020 Earnings (ADRO)
www.americanbankingnews.com - December 15 at 11:24 PM
Aduro BioTech Inc (ADRO) EVP Sells $528,958.53 in StockAduro BioTech Inc (ADRO) EVP Sells $528,958.53 in Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Aduro BioTech (ADRO) Given a $30.00 Price Target by Canaccord Genuity AnalystsAduro BioTech (ADRO) Given a $30.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - December 15 at 8:38 PM
FY2018 EPS Estimates for Aduro BioTech Inc (ADRO) Cut by Leerink SwannFY2018 EPS Estimates for Aduro BioTech Inc (ADRO) Cut by Leerink Swann
www.americanbankingnews.com - December 15 at 5:44 PM
William Blair Research Analysts Raise Earnings Estimates for Aduro BioTech Inc (ADRO)William Blair Research Analysts Raise Earnings Estimates for Aduro BioTech Inc (ADRO)
www.americanbankingnews.com - December 15 at 12:24 PM
Aduro BioTech Inc (ADRO) Given Consensus Rating of "Buy" by BrokeragesAduro BioTech Inc (ADRO) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 14 at 5:48 AM
Oppenheimer Trims Aduro BioTech (ADRO) Target Price to $13.00Oppenheimer Trims Aduro BioTech (ADRO) Target Price to $13.00
www.americanbankingnews.com - December 13 at 10:58 AM
Research Analysts Set Expectations for Aduro BioTech Incs Q1 2019 Earnings (ADRO)Research Analysts Set Expectations for Aduro BioTech Inc's Q1 2019 Earnings (ADRO)
www.americanbankingnews.com - December 12 at 10:32 PM
Aduro Biotech (ADRO) Will Not Continue Advancement of CRS-207 and Will Wind Down Trials - StreetInsider.comAduro Biotech (ADRO) Will Not Continue Advancement of CRS-207 and Will Wind Down Trials - StreetInsider.com
www.streetinsider.com - December 12 at 3:35 PM
Aduro Biotech Provides Update on CRS-207 Programs - GlobeNewswire (press release)Aduro Biotech Provides Update on CRS-207 Programs - GlobeNewswire (press release)
globenewswire.com - December 12 at 3:35 PM
Aduro Biotech to Host a Program Update CallAduro Biotech to Host a Program Update Call
finance.yahoo.com - December 12 at 11:22 AM
Aduro Biotech Provides Update on CRS-207 ProgramsAduro Biotech Provides Update on CRS-207 Programs
finance.yahoo.com - December 12 at 11:22 AM
Aduro BioTech (ADRO) PT Set at $15.00 by OppenheimerAduro BioTech (ADRO) PT Set at $15.00 by Oppenheimer
www.americanbankingnews.com - December 11 at 10:48 PM
BidaskClub Downgrades Aduro BioTech (ADRO) to SellBidaskClub Downgrades Aduro BioTech (ADRO) to Sell
www.americanbankingnews.com - December 9 at 10:36 AM
Jennifer Lew Sells 6,600 Shares of Aduro BioTech Inc (ADRO) StockJennifer Lew Sells 6,600 Shares of Aduro BioTech Inc (ADRO) Stock
www.americanbankingnews.com - December 4 at 9:34 PM
Aduro BioTech Inc (ADRO) COO Gregory W. Schafer Sells 20,000 SharesAduro BioTech Inc (ADRO) COO Gregory W. Schafer Sells 20,000 Shares
www.americanbankingnews.com - December 4 at 9:02 PM
Insider Selling: Aduro BioTech Inc (ADRO) EVP Sells 10,000 Shares of StockInsider Selling: Aduro BioTech Inc (ADRO) EVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - December 4 at 9:02 PM
Aduro BioTech Inc (ADRO) Insider Stephen T. Isaacs Sells 40,000 SharesAduro BioTech Inc (ADRO) Insider Stephen T. Isaacs Sells 40,000 Shares
www.americanbankingnews.com - December 4 at 9:02 PM
Aduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : December 4, 2017Aduro BioTech, Inc. – Value Analysis (NASDAQ:ADRO) : December 4, 2017
finance.yahoo.com - December 4 at 3:33 PM
Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : December 1, 2017Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : December 1, 2017
finance.yahoo.com - December 1 at 4:01 PM
ETFs with exposure to Aduro BioTech, Inc. : November 29, 2017ETFs with exposure to Aduro BioTech, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 11:19 AM

SEC Filings

Aduro BioTech (NASDAQ:ADRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aduro BioTech (NASDAQ:ADRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aduro BioTech (NASDAQ ADRO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.